-
The Journal of Dermatology Apr 1999Leukemia cutis is a specific skin lesion caused by infiltration of leukemic cells into the skin. It is uncommon in acute lymphocytic leukemia (ALL). It typically...
Leukemia cutis is a specific skin lesion caused by infiltration of leukemic cells into the skin. It is uncommon in acute lymphocytic leukemia (ALL). It typically manifests as red or violaceous papules, nodules, or plaques, mainly on the face. Leukemia cutis presenting with a generalized viral exanthem-like maculopapular eruption appears to be rare in the English literature. We report such a case. A 19 year-old man presented with a generalized purpuric maculopapular eruption of eight day's duration. Hematologic studies showed changes of acute lymphocytic leukemia, T-cell type. A skin biopsy specimen revealed a cuff-like, dense, perivascular infiltration of atypical lymphocytes in the upper and mid-dermis, consistent with leukemia cutis. The rash resolved in two weeks after chemotherapy. Our case illustrates that leukemia cutis should be considered in the differential diagnosis of a generalized morbilliform viral exanthem-like eruptions. Skin biopsy is important in establishing the diagnosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Diagnosis, Differential; Humans; Leukemic Infiltration; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Skin; Skin Diseases, Viral; Treatment Outcome
PubMed: 10343465
DOI: 10.1111/j.1346-8138.1999.tb03459.x -
Annals of Hematology Sep 2023The objective of this study is to explore the clinical features and outcomes of pediatric patients with acute lymphoblastic leukemia (ALL) harboring JAK-STAT signaling...
The objective of this study is to explore the clinical features and outcomes of pediatric patients with acute lymphoblastic leukemia (ALL) harboring JAK-STAT signaling pathway genetic abnormalities. This retrospective case series examined the clinical data of pediatric patients diagnosed with ALL harboring JAK-STAT pathway genetic abnormality at the Children's Hospital of the Capital Institute of Pediatrics between January 2016 and January 2022. Bone marrow next-generation sequencing was used to reveal the JAK pathway abnormalities. Descriptive statistics were used. From 432 children with ALL during the study period, eight had JAK-STAT pathway genetic abnormalities. Regarding immunotyping, there were four patients with common-B cell types and one with pre-B cell type. The three patients with T-ALL had early T-cell precursor(ETP) type, pre-T cell type, and T cell type. Gene mutations were more common than fusion genes. There was no central nervous system involvement in eight patients. All patients were considered at least at intermediate risk before treatments. Four patients underwent hematopoietic stem cell transplantation (HSCT). One child had a comprehensive relapse and died. The child had a severe infection and could not tolerate high-intensity chemotherapy. Another child relapsed 2 years after HSCT and died. Disease-free survival was achieved in six children. JAK-STAT pathway genetic abnormalities in pediatric Ph-like ALL are rare. Special attention should be paid to treatment-related complications, such as infection and combination therapy (chemotherapy, small molecule targeted drugs, immunotherapy, etc.) to reduce treatment-related death and improve long-term quality of life.
Topics: Humans; Child; Janus Kinases; Retrospective Studies; Quality of Life; Signal Transduction; STAT Transcription Factors; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Hematopoietic Stem Cell Transplantation
PubMed: 37209119
DOI: 10.1007/s00277-023-05245-y -
Hematology/oncology Clinics of North... Dec 2000Overall, the MRC Adult Leukaemia Trials have been successful, in that since the 1970s they have demonstrated a stepwise improvement in outcome. Examination of the... (Comparative Study)
Comparative Study Review
Overall, the MRC Adult Leukaemia Trials have been successful, in that since the 1970s they have demonstrated a stepwise improvement in outcome. Examination of the survival curves shows the DFS rate at 5 years in UKALL Trial 1 of 5% rising to 38% in UKALL Trial XII (year 2000). Unfortunately, compared with children with ALL, these results in adults must be regarded as poor, because in the UKALL children's trials the EFS rate at 5 years for a child entered in the year 2000 is expected to be above 80%. With a low proportion of all adults entered into randomized trials, one cannot be certain that improvements result from treatment rather than patient selection. Only recently have randomized trials in adults become large enough to detect plausible treatment effects. The authors believe that the main contribution of these trials so far, confirmed by other groups, is in examining prognostic features in al patients and finding that age and the presence of the Ph chromosome, independent of WBC count, gender, and cell type, is the main feature for predicting outcome. The UKALL XII trial will provide valuable information on the relative merits of transplantation and molecular studies of MRD. An in-depth study of a large number of Ph chromosome-positive ALL leukemias will also provide information on which to base future studies. Preliminary data suggest that all Ph-positive patients should undergo some sort of allograft early after CR is achieved, because these patients are not rescued by BMT after relapse. At the time of the publication of this article, preliminary studies suggest that STIs may not be as effective in Ph-positive ALL as in chronic granulocytic leukemia. The challenge for the future is to understand the biologic role of age and its impact on outcome so as to overcome "ageism" in adult ALL.
Topics: Adolescent; Adult; Age Factors; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Central Nervous System Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cranial Irradiation; Data Collection; Forecasting; Humans; Middle Aged; Multicenter Studies as Topic; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Transplantation, Homologous; Treatment Outcome; United Kingdom
PubMed: 11147226
DOI: 10.1016/s0889-8588(05)70189-1 -
Molecular Biology Reports Jan 2021Acute lymphocytic leukemia (ALL) is one of the subtypes of leukemia; it is one of the leading causes of malignancy and morbidity and childhood mortality. This study...
Acute lymphocytic leukemia (ALL) is one of the subtypes of leukemia; it is one of the leading causes of malignancy and morbidity and childhood mortality. This study examined the dysregulation of DROSHA and its clinical implications in ALL. In the case-control investigation, we have included 140 samples, consisting of 70 peripheral whole blood samples diagnosed with ALL and 70 age and sex-matched healthy children, to assess the level of expression of DROSHA mRNA between two groups. Quantitative Real-Time PCR was used to establish the level of DROSHA gene expression in the patients and controls. The results revealed that DROSHA was overexpressed in patients compared with controls (p < 0.001). There were no major differences between DROSHA expression and demographic factors and clinicopathological parameters (p > 0.001). The finding of the study revealed that DROSHA expression in ALL patients is significantly up-regulated; which is suggesting that may be served as a critical role in the pathogenesis of ALL. Also, DROSHA will possibly be utilized as a novel therapeutic target for ALL patients within the future.
Topics: Adolescent; Child; Child, Preschool; Female; Gene Expression Regulation, Neoplastic; Humans; Infant; Male; Pediatrics; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Ribonuclease III
PubMed: 33389538
DOI: 10.1007/s11033-020-06072-4 -
Future Oncology (London, England) Aug 2016
Review
Topics: Antineoplastic Agents; Bortezomib; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma
PubMed: 27173950
DOI: 10.2217/fon-2016-0126 -
Southern Medical Journal Jul 2003
Topics: Biopsy, Needle; Bone Marrow; Causality; Chickenpox; Diagnosis, Differential; Humans; Neutropenia; Pancytopenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma
PubMed: 12940335
DOI: 10.1097/01.SMJ.0000078656.67002.B0 -
Journal of Pediatric Nursing Apr 2003Advances in treatment and prognosis of childhood leukemia are considered a remarkable success of modern medicine. Childhood leukemia, once considered a universally fatal... (Comparative Study)
Comparative Study Review
Advances in treatment and prognosis of childhood leukemia are considered a remarkable success of modern medicine. Childhood leukemia, once considered a universally fatal disease, now boasts overall cure rates ranging from 75% to 85% for acute lymphocytic leukemia (ALL) and cure rates approaching 40% to 50% for acute myelogenous leukemia (AML). Inherent to this success is the expertise nurses provide when caring for children with leukemia. Understanding the classifications of leukemia and the specific therapies help direct the specialized care children with leukemia need. This article provides an overview of childhood leukemias, diagnostic and classification methods used to differentiate and evaluate childhood leukemias, and treatment strategies applied toward various forms of childhood leukemias.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neoplasm Staging; Nursing Assessment; Nursing Diagnosis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Risk Assessment; Survival Rate; Treatment Outcome
PubMed: 12720205
DOI: 10.1053/jpdn.2003.9 -
Leukemia Research Dec 2022
A single flow cytometric MRD measurement in children with B-lineage acute lymphocytic leukemia and hyperleukocytosis redefines the requirements of high-risk treatment: Results of the study ALL-MB 2008.
Topics: Child; Humans; Flow Cytometry; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Neoplasm, Residual
PubMed: 36332292
DOI: 10.1016/j.leukres.2022.106982 -
Annals of Oncology : Official Journal... 1993
Review
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Autologous; Transplantation, Homologous
PubMed: 8338797
DOI: 10.1093/annonc/4.suppl_1.s81 -
Clinical Nuclear Medicine Sep 2019PSMA PET/CT is known to show uptake in various benign and malignant processes. The following PSMA PET/CT was performed for prostate carcinoma staging (Gleason 3 + 4 left...
PSMA PET/CT is known to show uptake in various benign and malignant processes. The following PSMA PET/CT was performed for prostate carcinoma staging (Gleason 3 + 4 left apex; PSA 5.8). It shows incidental diffuse PSMA marrow uptake, not typical for prostate metastatic disease. No treatment had been commenced at the time of the scan. Serology and bone marrow biopsy showed B-cell acute lymphocytic leukemia. Focal PSMA uptake in the right ischium was correlated with a T1 hypointense lesion on a previous MRI and was convincing for a skeletal metastasis. Alternative diagnoses in diffuse skeletal PSMA uptake need therefore to be considered.
Topics: Aged; Glutamate Carboxypeptidase II; Humans; Incidental Findings; Male; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms
PubMed: 31306192
DOI: 10.1097/RLU.0000000000002712